Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Winder

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and RadiationPierre Bohanes, Cathryn J Rankin, Charles D Blanke, et al.
Wiener Klinische Wochenschrift|February 16, 2022
SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria : Findings of a multicentric nationwide studyJulia M Berger, Phillipp Wohlfarth, Oliver Königsbrügge, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical dataPatrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2018
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized MicePratiksha Gulati, Julia Rühl, Abhilash Kannan, et al.
Annals of Hematology|March 4, 2024
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignanciesPatrick Reimann, Verena Petzer, Axel Mündlein, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional studyJakob Michael Riedl, Florian Posch, Gerald Prager, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2020
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional studyGerald W Prager, Leopold Oehler, Armin Gerger, et al.
Journal for Immunotherapy of Cancer|December 14, 2023
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort studyDominik A Barth, Florian Moik, Sarah Steinlechner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) StudySebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, et al.
The New England Journal of Medicine|October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung CancerJohn V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and RadiationPierre Bohanes, Cathryn J Rankin, Charles D Blanke, et al.
Wiener Klinische Wochenschrift|February 16, 2022
SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria : Findings of a multicentric nationwide studyJulia M Berger, Phillipp Wohlfarth, Oliver Königsbrügge, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical dataPatrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2018
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized MicePratiksha Gulati, Julia Rühl, Abhilash Kannan, et al.
Annals of Hematology|March 4, 2024
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignanciesPatrick Reimann, Verena Petzer, Axel Mündlein, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional studyJakob Michael Riedl, Florian Posch, Gerald Prager, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2020
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional studyGerald W Prager, Leopold Oehler, Armin Gerger, et al.
Journal for Immunotherapy of Cancer|December 14, 2023
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort studyDominik A Barth, Florian Moik, Sarah Steinlechner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) StudySebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, et al.
The New England Journal of Medicine|October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung CancerJohn V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Pageof 10